Edition:
United Kingdom

Vericel Corp (VCEL.OQ)

VCEL.OQ on NASDAQ Stock Exchange Capital Market

16.88USD
5:10pm GMT
Change (% chg)

$-0.22 (-1.29%)
Prev Close
$17.10
Open
$17.20
Day's High
$17.34
Day's Low
$16.66
Volume
58,016
Avg. Vol
282,643
52-wk High
$18.84
52-wk Low
$4.65

Summary

Name Age Since Current Position

Robert Zerbe

67 2012 Independent Chairman of the Board

Dominick Colangelo

54 2014 President, Chief Executive Officer, Director

Gerard Michel

54 2014 Chief Financial Officer, Vice President - Corporate Development

Daniel Orlando

52 2013 Chief Operating Officer, Chief Commercial Officer

Jonathan Hopper

53 2018 Chief Medical Officer

Steven Gilman

65 2017 Independent Director

Heidi Hagen

49 2017 Independent Director

Kevin McLaughlin

61 2017 Independent Director

Alan Rubino

63 2005 Independent Director

Paul Wotton

57 2017 Independent Director

Biographies

Name Description

Robert Zerbe

Dr. Robert L. Zerbe, M.D., is an Independent Chairman of the Board of the company. Dr. Zerbe is the Chief Executive Officer of QUATRx Pharmaceuticals Company, a venture-backed drug development company which he co-founded in 2000. Prior to his role at QUATRx, Dr. Zerbe held several senior executive management positions with major pharmaceutical companies including Eli Lilly (from 1982 to 1993) and Pfizer (formerly Parke-Davis) (from 1993 to 2000). During his tenure at Eli Lilly, Dr. Zerbe's clinical research and development positions included Managing Director, Lilly Research Center U.K., and Vice President of Clinical Investigation and Regulatory Affairs. He joined Parke Davis in 1993, becoming Senior Vice President of Worldwide Clinical Research and Development. In this capacity he led the clinical development programs for a number of key products, including Lipitor® and Neurontin®. Dr. Zerbe received his M.D. from the Indiana University School of Medicine, and has completed post-doctoral work in internal medicine, endocrinology and neuroendocrinology at Indiana University and the National Institutes of Health. He also serves on the board of directors of, Edgemont Pharmaceuticals, a private specialty pharmaceutical company. The Board of Directors believes Dr. Zerbe's qualifications to sit on our Board of Directors include his management positions at major pharmaceutical companies, including the experience he gleaned in his clinic development roles.

Dominick Colangelo

Mr. Dominick C. Colangelo is the President, Chief Executive Officer, and Director of the Company. Mr. Colangelo joined Vericel Corporation in 2013 with more than twenty years of executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly and Company. Most recently, he was President and Chief Executive Officer of Promedior, Inc. from 2009 to 2012. During his career, he has held a variety of executive positions of increasing responsibility in product development, pharmaceutical operations, sales and marketing, and corporate development. He has extensive experience in the acquisition, development and commercialization of therapies to treat fibrovascular, metabolic and cardiovascular diseases. During his tenure at Eli Lilly and Company, he held positions as Director of Strategy and Business Development for Lilly’s Diabetes Product Group and also served as a founding Managing Director of Lilly Ventures. Mr. Colangelo received his B.S.B.A. in Accounting, Magna Cum Laude, from the State University of New York at Buffalo and a J.D. degree, with Honors, from the Duke University School of Law. The Board of Directors believes Mr. Colangelo's qualifications to sit on our Board of Directors include his significant contributions within the biopharmaceutical industry.

Gerard Michel

Mr. Gerard Michel is the Chief Financial Officer, Vice President - Corporate Development of the Company. Mr. Michel joined Vericel in June of 2014 with over 25 years of experience in the pharmaceutical industry across multiple functional areas. He has considerable experience in business development, raising capital and executing successful financial transactions. Mr. Michel was formerly chief financial officer and vice president, corporate development of Biodel from November 2007 to May 2014, where he oversaw strategic development, fundraising and capital structure management, marketing efforts, investor relations, and financial reporting and internal controls. Prior to his role at Biodel, from August 2002 to November 2007, Mr. Michel served as chief financial officer and vice president of corporate development of NPS Pharmaceuticals, where he led the first syndicated royalty monetization. Prior to that, Mr. Michel was a Principal at Booz Allen Hamilton Inc. and also held a variety of commercial roles at both Lederle Labs and Wyeth Labs. Mr. Michel holds an M.S. in Microbiology from the University of Rochester School of Medicine, an M.B.A. from the Simon School of Business, and a B.S. in both Biology and Geology from the University of Rochester.

Daniel Orlando

Mr. Daniel R. Orlando is the Chief Operating Officer, Chief Commercial Officer of the company. Mr. Orlando joined Vericel as Chief Commercial Officer in August of 2012. Mr. Orlando served as interim Chief Executive Officer of Vericel from December 2012 to March 2013. He has more than 20 years of commercial product preparation and launch experience including leadership roles in sales, marketing and most recently as a vice president of business development for North and South America at Takeda Pharmaceuticals. As an early employee at Takeda North America, he served as the original brand director for Actos, which became the #1 branded anti-diabetic agent in the United States. Mr. Orlando’s initial pharmaceutical experience came in progressively expanding roles in sales and marketing at Abbott Laboratories. He holds an MBA from Florida Atlantic University and a BA in Economics with Honors from the University of Florida.

Jonathan Hopper

Dr. Jonathan Mark Hopper is the Chief Medical Officer of the Company. Dr. Hopper formerly served as Senior Medical Director, Orthopedic Clinical Development for Ferring Pharmaceuticals, where he was responsible for establishing and executing the company's strategy for Orthopedic clinical development. Prior to joining Ferring Pharmaceuticals, he served in a number of senior medical roles including Vice President, Global Medical Director for Stryker Corporation. Dr. Hopper also has significant medical device regulatory experience having served as a Senior Medical Officer for the UK Medicines and Healthcare products Regulatory Agency. Dr. Hopper graduated with a M.B. Ch.B. from Birmingham University Medical School UK, is a Fellow of the Royal College of Surgeons, Edinburgh, and attained an M.B.A. at Keele University UK.

Steven Gilman

Dr. Steven C. Gilman, Ph.D., is an Independent Director of the company Dr. Gilman is the Director of Company. Dr. Gilman served as Senior Vice President, Discovery & Non-Clinical Development and Chief Scientific Officer. Prior to joining Cubist, Dr. Gilman served as Chairman of the board of directors and CEO of ActivBiotics, a privately held biopharmaceutical company. Previously, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including Vice President and General Manager, Inflammation, responsible for all aspects of the Inflammation business from early gene discovery to product commercialization. Prior to Millennium, he was Group Director at Pfizer Global Research and Development, where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas. Dr. Gilman has also held scientific, business, and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School, and Connecticut College. He currently serves on the board of directors of the Massachusetts Biotechnology Association and Inhibikase, Inc., a privately held biotechnology company. In addition, Dr. Gilman currently serves on the board of directors of SYNEXIS, Inc., the Massachusetts Biotechnology Association and Inhibikase, Inc., a privately held biotechnology company and the Penn State University Biotechnology Advisory Board. Dr. Gilman received his Ph.D. and M.S. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio. The Board of Directors believes Dr. Gilman's qualifications to sit on our Board of Directors include his leadership roles in the biopharmaceutical industry in a wide range of positions.

Heidi Hagen

Ms. Heidi Hagen is an Independent Director of the company Ms. Hagen is the Director of the compnay, effective August 23, 2013. Ms. Hagen is global chief operating officer at Sotio LLC, since 2013, a biotechnology company developing new therapies for the treatment of cancer and autoimmune diseases using its immunotherapy platform and proprietary cell-based technologies. Previously Ms. Hagen was senior vice president, operations, at Dendreon Corporation, from 2002 to 2012, where she was responsible for, among other duties, manufacturing and supply chain operations. Prior to joining Dendreon, Ms. Hagen spent nearly ten years at Immunex Corporation, where she held several positions in drug development and supply chain and operations management. Ms. Hagen earned her B.S. in cell and molecular biology, M.S. in bioengineering, and MBA at the University of Washington. The Board of Directors believes Ms. Hagen's qualifications to sit on our Board of Directors include her leadership roles in the biotechnology industry in a wide range of positions.

Kevin McLaughlin

Mr. Kevin F. McLaughlin is an Independent Director of company. Mr. McLaughlin is the Director of Company. Before joining Acceleron in November 2010, Mr. McLaughlin is the Senior Vice President, Chief Financial Officer and Treasurer at Acceleron Pharma. He most recently served as Senior Vice President and Chief Financial Officer of Qteros, Inc., a cellulosic biofuels company. He was a co-founder of Aptius Education, Inc. and from 2007 through 2009 he worked as the Chief Operating Officer and a director. From 1996 through 2007, Mr. McLaughlin held several executive positions with PRAECIS Pharmaceuticals, Inc. He joined PRAECIS as their first Chief Financial Officer where he had responsibility for private financings, partnership financings, the company's initial public offering and subsequent stock offering. Later, Mr. McLaughlin became COO, and then President and CEO, and he served as a member of the board of directors. In this capacity he was responsible for negotiating the sale of the company to GlaxoSmithKline. He began his career in senior financial roles at Prime Computer and Computervision Corporation. Mr. McLaughlin received a BS in business from Northeastern University and an MBA from Babson College. The Board of Directors believes Mr. McLaughlin's qualifications to sit on our Board of Directors include his leadership roles in the biopharmaceutical industry in a wide range of positions.

Alan Rubino

Mr. Alan L. Rubino is an Independent Director of the company. Prior to joining Emisphere, Mr. Rubino served as Chief Executive Officer and President of New American Therapeutics, Inc., a specialty pharmaceutical company, since October 2010 where he led the acquisition of penciclovir from Novartis AG. He and his team re-marketed the product and significantly advanced its sale, which resulted in a return to the company's investors. Previously, Mr. Rubino served as the Chief Executive Officer and President of Akrimax Pharmaceuticals, LLC, an integrated specialty pharmaceutical company, since February 2008. Prior to this he served as President and Chief Operating Officer of Pharmos Corporation, a biopharmaceutical company, from November 2005 to December 2007. Mr. Rubino has continued to expand upon a highly successful and distinguished career that included Hoffmann-La Roche, Inc., a research-focused healthcare company. He received Bachelor of Arts degree in economics from Rutgers University with a minor in biology/chemistry and also completed post-graduate educational programs at the University of Lausanne and Harvard Business School. Additionally, he serves on the Board of Rutgers University School of Business and the Lerner Center for Pharmaceutical Studies. Mr. Rubino has also served as a member of the Board of Directors of SANUWAVE Health, Inc. since 2014, and since May 2010 of Genisphere, Inc., a private company that provides a nanotechnology platform for targeted drug delivery, a method of delivering medication to a patient that increases the concentration of the medication in targeted parts of the body. The Board of Directors believes Mr. Rubino's qualifications to sit on our Board of Directors include his leadership roles in the life sciences industry in a wide range of positions, including positions focused on sales and marketing and SEC matters.

Paul Wotton

Dr. Paul K. Wotton, Ph.D., is an Independent Director of the company. Dr. Wotton is the Director of Company. Prior to joining Ocata in 2014, Dr. Wotton serves as the President and CEO of Ocata Therapeutics, joining the company in July 2014. Prior to Ocata, Dr. Wotton had served as President and CEO of Antares Pharma Inc. (NASDAQ: ATRS), since October, 2008. Prior to joining Antares, Dr. Wotton was the CEO of Topigen Pharmaceuticals and prior to Topigen, he was the Global Head of Business Development of SkyePharma PLC. Earlier in his career he held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. Dr. Wotton is also past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada. Dr. Wotton received his Ph.D. in pharmaceutical sciences from the University of Nottingham. In 2014 he was named New Jersey EY Entrepreneur of the Year in Life Sciences. The Board of Directors believes Dr. Wotton's qualifications to sit on our Board of Directors include his leadership roles in the life sciences industry in a wide range of positions.

Basic Compensation

Name Fiscal Year Total

Robert Zerbe

111,817

Dominick Colangelo

1,474,030

Gerard Michel

726,433

Daniel Orlando

685,833

Jonathan Hopper

--

Steven Gilman

78,317

Heidi Hagen

88,317

Kevin McLaughlin

91,317

Alan Rubino

95,317

Paul Wotton

76,817
As Of  31 Dec 2017